Fulgent Genetics Inc
FLGT26.720USD
-0.290-1.07%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
824.42MMarket Cap
LossP/E TTM
More Details of Fulgent Genetics Inc Company
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Fulgent Genetics Inc Info
Ticker SymbolFLGT
Company nameFulgent Genetics Inc
IPO dateSep 28, 2016
CEOHsieh (Ming)
Number of employees1313
Security typeOrdinary Share
Fiscal year-endSep 28
Address4399 Santa Anita Ave
CityEL MONTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91731
Phone16263500537
Websitehttps://www.fulgentgenetics.com/
Ticker SymbolFLGT
IPO dateSep 28, 2016
CEOHsieh (Ming)
Company Executives of Fulgent Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.76M
-0.06%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
869.55K
-0.12%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
228.63K
-0.49%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
213.20K
-0.53%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
18.11K
+98.39%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
12.23K
+276.37%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
10.51K
+74.68%
Ms. Melanie Solomon
Ms. Melanie Solomon
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.76M
-0.06%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
869.55K
-0.12%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
228.63K
-0.49%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
213.20K
-0.53%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
18.11K
+98.39%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
12.23K
+276.37%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Institutional
45.62M
55.77%
Insurance
34.38M
42.03%
Patient
1.80M
2.20%
By RegionUSD
Name
Revenue
Proportion
United States
76.21M
93.16%
Foreign
5.60M
6.84%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Institutional
45.62M
55.77%
Insurance
34.38M
42.03%
Patient
1.80M
2.20%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hsieh (Ming)
28.33%
BlackRock Institutional Trust Company, N.A.
6.45%
Millennium Management LLC
4.75%
The Vanguard Group, Inc.
3.80%
Acadian Asset Management LLC
3.69%
Other
52.99%
Shareholders
Shareholders
Proportion
Hsieh (Ming)
28.33%
BlackRock Institutional Trust Company, N.A.
6.45%
Millennium Management LLC
4.75%
The Vanguard Group, Inc.
3.80%
Acadian Asset Management LLC
3.69%
Other
52.99%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.70%
Investment Advisor/Hedge Fund
20.23%
Investment Advisor
19.92%
Hedge Fund
12.93%
Research Firm
3.36%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.28%
Pension Fund
0.21%
Venture Capital
0.05%
Other
10.02%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
412
16.53M
59.35%
--
2025Q3
439
16.53M
59.80%
-4.75K
2025Q2
463
16.58M
62.72%
-126.14K
2025Q1
472
16.61M
64.18%
-3.20M
2024Q4
474
17.50M
62.81%
+892.69K
2024Q3
488
16.58M
60.31%
+907.77K
2024Q2
524
15.67M
60.02%
+492.38K
2024Q1
543
15.20M
57.74%
-2.06M
2023Q4
574
14.77M
58.48%
+87.68K
2023Q3
579
14.65M
57.50%
+460.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hsieh (Ming)
8.76M
28.62%
-6.40K
-0.07%
Aug 26, 2025
BlackRock Institutional Trust Company, N.A.
1.62M
5.3%
-69.12K
-4.09%
Jun 30, 2025
Millennium Management LLC
1.44M
4.71%
--
--
Jul 29, 2025
The Vanguard Group, Inc.
1.16M
3.79%
-4.25K
-0.37%
Jun 30, 2025
Acadian Asset Management LLC
1.12M
3.65%
+311.98K
+38.71%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.13M
3.71%
+105.42K
+10.25%
Jun 30, 2025
Gao (Hanlin)
873.75K
2.85%
-1.06K
-0.12%
Sep 03, 2025
BlackRock Financial Management, Inc.
280.92K
0.92%
-4.69K
-1.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
476.49K
1.56%
+36.47K
+8.29%
Jun 30, 2025
DWS Investments UK Limited
330.56K
1.08%
+112.51K
+51.60%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Health Care Services ETF
0.72%
Global X Genomics & Biotechnology ETF
0.5%
ALPS Medical Breakthroughs ETF
0.28%
iShares US Small Cap Value Factor ETF
0.23%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.08%
iShares U.S. Healthcare Providers ETF
0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Goldman Sachs Innovate Equity ETF
0.05%
View more
State Street SPDR S&P Health Care Services ETF
Proportion0.72%
Global X Genomics & Biotechnology ETF
Proportion0.5%
ALPS Medical Breakthroughs ETF
Proportion0.28%
iShares US Small Cap Value Factor ETF
Proportion0.23%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.08%
iShares U.S. Healthcare Providers ETF
Proportion0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.07%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.05%
Goldman Sachs Innovate Equity ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Fulgent Genetics Inc?
The top five shareholders of Fulgent Genetics Inc are:
Hsieh (Ming) holds 8.76M shares, accounting for 28.62% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.62M shares, accounting for 5.30% of the total shares.
Millennium Management LLC holds 1.44M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 3.79% of the total shares.
Acadian Asset Management LLC holds 1.12M shares, accounting for 3.65% of the total shares.
Hsieh (Ming) holds 8.76M shares, accounting for 28.62% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.62M shares, accounting for 5.30% of the total shares.
Millennium Management LLC holds 1.44M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 1.16M shares, accounting for 3.79% of the total shares.
Acadian Asset Management LLC holds 1.12M shares, accounting for 3.65% of the total shares.
What are the top three shareholder types of Fulgent Genetics Inc?
The top three shareholder types of Fulgent Genetics Inc are:
Hsieh (Ming)
BlackRock Institutional Trust Company, N.A.
Millennium Management LLC
Hsieh (Ming)
BlackRock Institutional Trust Company, N.A.
Millennium Management LLC
How many institutions hold shares of Fulgent Genetics Inc (FLGT)?
As of 2025Q4, 412 institutions hold shares of Fulgent Genetics Inc, with a combined market value of approximately 16.53M, accounting for 59.35% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.46%.
What is the biggest source of revenue for Fulgent Genetics Inc?
In FY2025Q2, the Institutional business generated the highest revenue for Fulgent Genetics Inc, amounting to 45.62M and accounting for 55.77% of total revenue.
